Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness in Real-World and Clinical Settings at IDWeek 2023
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
Japanese pharmaceutical company Shionogi & Co. and the Medicines Patent Pool (MPP), a United Nations-backed international public health organisation, have announced that MPP has signed seven sublicence agreements for Shionogi's ensitrelvir fumaric acid, a COVID antiviral currently approved in Japan and being evaluated in clinical trials outside of Japan.
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data and Exploratory Long COVID Data at CROI
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
Feb 15 (Reuters) - The U.S. National Institutes of Health (NIH) said on Wednesday that it had started a clinical trial to evaluate Japan's Shionogi & Co Ltd's (4507.T) experimental oral antiviral drug to treat COVID-19.
Shionogi & Co. has entered into an additional purchasing contract of Xocova (Generic name: ensitrelvir fumaric acid), that recently obtained emergency regulatory approval in Japan for the indication of SARS-CoV-2 infection , with the Ministry of Health, Labour and Welfare (MHLW) on December 12, 2022.